Long-term therapy with low-molecular-weight heparin (LMWH) is the treatment of choice for cancer patients with venous thromboembolism (VTE). However, the ideal doses of LMWH have not been thoroughly studied. We used the RIETE Registry data to assess the influence of the daily LMWH dosage on outcome during the first three months after VTE. We used propensity score-matching to compare patients who received <150 vs. those receiving 65150 UI/kg/day LMWH. Up to July 2010, 3,222 cancer patients with VTE received long-term therapy with fixed doses of LMWH. Of these, 1,472 (46%) received <150 IU/kg/day (mean, 112 \ub1 28), and 1,750 received 65150 IU/kg/day (mean, 184 \ub1 32). Results of the propensity score matching involved 1269 matched pairs....
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...
The advantages of low-molecular weight heparin (LMVVH) over warfarin, in the treatment of cancer ass...
Background: Since 2004, guidelines recommend long-term treatment with low-molecular-weight heparin (...
International audienceSUMMARY BACKGROUND: Cancer patients with venous thromboembolism (VTE) are at h...
Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromb...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
Background: The use of low-molecular-weight heparin (LMWH) for long-term therapy of venous thromboem...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
International audienceINTRODUCTION: Patients with cancer-associated thrombosis are at a high risk of...
Background: Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4...
Background: Since 2004, international guidelines provide specific recommendations for patients with ...
Low-molecular-weight heparin (LWMH) is recommended as the preferred anticoagulant treatment over vit...
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...
The advantages of low-molecular weight heparin (LMVVH) over warfarin, in the treatment of cancer ass...
Background: Since 2004, guidelines recommend long-term treatment with low-molecular-weight heparin (...
International audienceSUMMARY BACKGROUND: Cancer patients with venous thromboembolism (VTE) are at h...
Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromb...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
Background: The use of low-molecular-weight heparin (LMWH) for long-term therapy of venous thromboem...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer...
International audienceINTRODUCTION: Patients with cancer-associated thrombosis are at a high risk of...
Background: Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4...
Background: Since 2004, international guidelines provide specific recommendations for patients with ...
Low-molecular-weight heparin (LWMH) is recommended as the preferred anticoagulant treatment over vit...
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Current guidelines of antithrombotic therapy suggest early initiation of vitamin K antagonists (VKA)...
Abstract Background Cancer and its therapies increase the risk of venous thromboembolism. Compared t...